Our work spans structure-based drug design, molecular simulations, ADMET and toxicity prediction, and computational risk assessment for critical development challenges such as solubility, stability, bioequivalence, and degradation liabilities. Growdea’s platforms and services are designed to de-risk experimental programs early, reduce cost and timelines, and support QbD-aligned decision making rather than replace experiments. We have successfully delivered multiple projects with experimental validation confirming nanomolar activity of compounds identified through our computational workflows, demonstrating real-world impact of our in-silico capabilities.